Purpose: To demonstrate a H/ P whole human brain volume coil configuration for 3 Tesla with separate P transmit and receive components that maintains H MRS performance and delivers optimal P MRSI with H decoupling.
Methods: We developed an 8-channel P receive array coil covering the head to be used as an insert for a commercial double-tuned H/ P birdcage transmit-receive coil. This retains the possibility of using low-power rectangular pulses for H-decoupled 3D P MRSI (nominal resolution 17.6 cm ; acquisition duration 13 min) but increases the SNR with the receive sensitivity of P surface coils. The performance of the combined coil setup was evaluated by measuring H and P SNR with and without the P receive array and by assessing the effect of the receive array on the transmit efficiencies of the birdcage coil.
Results: Compared to the birdcage coil alone, the P insert in combination with the birdcage achieved an average P SNR gain of 1.4 ± 0.4 in a center partition of the brain. The insert did not cause losses in H MRS performance and transmit efficiency, whereas for P approximately 20% more power was needed to achieve the same γB1.
Conclusion: The new coil configuration allows H MRSI and optimal H-decoupled 3D P MRSI, with increased SNR of the human brain without patient repositioning, for clinical and research purposes at 3 Tesla.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520216 | PMC |
| http://dx.doi.org/10.1002/mrm.27736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters.
Nat Genet
January 2025
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Members of the KMT2C/D-KDM6A complex are recurrently mutated in urothelial carcinoma and in histologically normal urothelium. Here, using genetically engineered mouse models, we demonstrate that Kmt2c/d knockout in the urothelium led to impaired differentiation, augmented responses to growth and inflammatory stimuli and sensitization to oncogenic transformation by carcinogen and oncogenes. Mechanistically, KMT2D localized to active enhancers and CpG-poor promoters that preferentially regulate the urothelial lineage program and Kmt2c/d knockout led to diminished H3K4me1, H3K27ac and nascent RNA transcription at these sites, which leads to impaired differentiation.
View Article and Find Full Text PDFBrief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors.
JTO Clin Res Rep
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown.
Methods: We collected clinical, pathologic, and demographic variables from five institutions for patients whose tumors met criteria for SMARCA4-UTs (undifferentiated phenotype and loss of SMARCA4 (BRG1) by immunohistochemistry).
Results: We identified 92 patients with SMARCA4-UTs; 58 (63%) had stage IV disease at diagnosis and 16 (17%) developed recurrent or metastatic disease after initial diagnosis.
Nutrition Care in Cancer: An Overlooked Part of Patient-Centered Care.
Semin Oncol Nurs
January 2025
Bavarian Cancer Research Center and CCC Munich LMU, LMU Hospital Munich, Germany.
Objectives: Robust evidence highlights the crucial role of nutrition for people with cancer, and international organizations recognize it as a basic human right linked to health and food. Within this context, we aim to emphasize the critical role of nutrition care for cancer patients and to highlight the essential contributions of nurses in providing patient-centered nutrition care.
Methods: This opinion paper synthesizes evidence and perspectives from peer-reviewed articles and position papers.
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
December 2024
Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address:
Background: FGFR2/3, MTAP and ERBB2 genomic alterations have treatment targets in advanced urothelial carcinoma (aUC). These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC.
Patients And Methods: We identified patients with available genomic data in our multi-institution cohort of patients with aUC treated with ICI.
Beyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.
J Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!